Signet Therapeutics is a Shenzhen-based clinical-stage biotech founded in late 2020 by a team from the Dana-Farber Cancer Institute that develops first-in-class targeted cancer therapies using patient-derived organoid disease models combined with AI-driven target discovery and compound screening. Its lead asset SIGX1094, a FAK/SRC dual inhibitor for diffuse gastric cancer, is in Phase I trials with FDA Orphan Drug and Fast Track designations, and a pipeline of five first-in-class programs extends into cardiac and kidney disease targets. The company also provides its organoid platform to pharmaceutical and research partners for preclinical drug discovery and cardiotoxicity prediction.
1
Round
1
Industry
5
Tags
Nov 4, 2026
Latest raise
Funding activity · 1 round
Nov 4, 2026
Series A
Led by China Life Equity Investment (国寿股权投资有限公司)
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
